Processing

Please wait...

Settings

Settings

Goto Application

1. WO2021236415 - SAFE POTENT SINGLE VECTOR PLATFORM VACCINE AGAINST COVID-19

Publication Number WO/2021/236415
Publication Date 25.11.2021
International Application No. PCT/US2021/032203
International Filing Date 13.05.2021
IPC
A61K 39/215 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
215Coronaviridae, e.g. avian infectious bronchitis virus
A61P 31/14 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
C07K 14/165 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
08RNA viruses
165Coronaviridae, e.g. avian infectious bronchitis virus
C07K 19/00 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
C12N 5/10 2006.1
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
10Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
CPC
A61K 2039/522
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
51comprising whole cells, viruses or DNA/RNA
52Bacterial cells; Fungal cells; Protozoal cells
522avirulent or attenuated
A61K 2039/523
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
51comprising whole cells, viruses or DNA/RNA
52Bacterial cells; Fungal cells; Protozoal cells
523expressing foreign proteins
A61K 2039/541
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
54characterised by the route of administration
541Mucosal route
A61K 39/12
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
12Viral antigens
A61P 31/14
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
12Antivirals
14for RNA viruses
C07K 14/005
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
005from viruses
Applicants
  • THE REGENTS OF THE UNIVERSITY OF CALIFORNIA [US]/[US]
Inventors
  • HORWITZ, Marcus, A.
  • JIA, Qingmei
Agents
  • WOOD, William, J.
Priority Data
63/026,48018.05.2020US
63/182,11130.04.2021US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) SAFE POTENT SINGLE VECTOR PLATFORM VACCINE AGAINST COVID-19
(FR) VACCIN À PLATE-FORME À VECTEUR UNIQUE, PUISSANT ET SÛR CONTRE LA COVID -19
Abstract
(EN) Embodiments of the invention include immunogenic compositions that comprise an attenuated recombinant Francisella tularensis subspecies holarctica Live Vaccine Strain (LVS) having a deletion in a polynucleotide encoding CapB (LVS ΔcapB), wherein the LVS ΔcapB expresses one or more antigens present on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Embodiments of the invention also include methods of immunizing a susceptible host against a pathogen comprising administering to the host a vaccine that comprises an attenuated recombinant Live Vaccine Strain lacking a polynucleotide encoding CapB (LVS ΔcapB), wherein the LVS ΔcapB expresses one or more antigens expressed by a severe acute respiratory syndrome coronavirus 2 (SAR8- CoV-2) polypeptide.
(FR) Selon certains modes de réalisation, l'invention concerne des compositions immunogènes qui comprennent une souche de vaccin vivant (LVS) atténuée recombinante de Francisella tularensis sous-espèce holarctica, ayant une délétion dans un polynucléotide codant pour CapB (LVS ΔcapB), la LVS ΔcapB exprimant un ou plusieurs antigènes présents sur le coronavirus 2 du syndrome respiratoire aigu sévère (SARS-CoV -2); selon d'autres modes de réalisation, l'invention concerne également des procédés d'immunisation d'un hôte réceptif contre un pathogène, comprenant l'administration à l'hôte d'un vaccin qui comprend une souche de vaccin vivant atténuée recombinante dépourvue de polynucléotide codant pour CapB (LVS ΔcapB), la LVS ΔcapB exprimant un ou plusieurs antigènes exprimés par un polypeptide du coronavirus 2 du syndrome respiratoire aigu sévère (SARS- CoV-2).
Latest bibliographic data on file with the International Bureau